Differences in endosomal Rab gene expression between positive and negative COVID-19 patientsCOVID-19 양성 및 음성 환자 간의 엔도솜 Rab 유전자 발현의 차이Article Published on 2022-07-152022-09-11 Journal: BMC Research Notes [Category] 유전자 메커니즘, [키워드] ACE2 analysed control group coronavirus coronavirus disease coronavirus disease-2019 COVID-19 COVID-19 patient difference endocytic Endocytic pathway epithelial etiologic agent expression Gene Expression groups host cell Infection internalization Mann Whitney U Test mRNA patients performed positive Proteins Rab Rab11b Rab5 Rab7 RNA RT-PCR SARS CoV SARS CoV-2 SARS CoV-2 infection significant difference significant differences significantly significantly increased Statistical tests Test viral entry virus [DOI] 10.1186/s13104-022-06144-7 PMC 바로가기 [Article Type] Article
[Change in serum IgG antibody during the recovery stage of Omicron variant infection in children: an analysis of 110 cases][소아 오미크론 변이체 감염 회복기 혈청 IgG 항체 변화 : 110건 분석]Article Published on 2022-07-152022-09-11 Journal: Zhongguo dang dai er ke za zhi = Chinese journal o [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age Analysis antibody BBIBP-CorV Beijing Biological Biological products booster vaccination caused Child children China Chinese citation Clinical data Complete coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 diagnosed Diagnosis disease dose doses English four group four groups groups IgG IgG antibody inactivated Inactivated vaccine Infection journal no significant difference no significant differences Nucleic acid detection omicron pediatrics protective effect RBD IgG Recovery stage reduction in respiratory Retrospective analysis route SARS-CoV-2 SARS-CoV-2 IgG antibody SARS-CoV-2 nucleic acid SARS-CoV-2 vaccination SARS-CoV-2 vaccine serum IgG Serum level severe acute respiratory syndrome Coronavirus Sex significant difference significant differences significantly higher significantly lower Sinopharm status the vaccine Tianjin Transmission two group two groups vaccination Vaccine variant was performed [DOI] 10.7499/j.issn.1008-8830.2204074 PMC 바로가기 [Article Type] Article
Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study질병 진행 위험이 높은 경증에서 중등도 COVID-19 환자를 대상으로 한 다양한 단일 클론 항체 요법의 임상 효능: 전향적 코호트 연구Observational Study Published on 2022-07-012022-09-11 Journal: European Journal of Clinical Microbiology & Infect [Category] COVID19(2023년), SARS, 변종, 임상, 진단, 치료기술, [키워드] (alpha 95% CI 95% confidence interval adjusted odds ratio analysed anti-SARS-CoV-2 antibody treatment B.1.1.7 bamlanivimab Bamlanivimab-etesevimab, casirivimab-imdevimab baseline Baseline serology Casirivimab circulating variants clinical Clinical outcome clinical outcomes combination regimen conducted COVID-19 COVID-19 outpatient COVID-19 outpatients COVID-19 progression disease Efficacy eight etesevimab Factor groups high risk high-risk population hospital hospitalisation hospitalised Imdevimab Italian Logistic regression mAb Medicine Mild Mild-to-moderate Mild-to-moderate COVID-19 outpatients Moderate COVID-19 monoclonal antibodies monoclonal antibody Monoclonal antibody treatments Monoclonal antibody treatments for COVID-19 multivariable no significant difference no significant differences non-hospitalised Outpatient Patient patient subgroup patients progression proportion prospective cohort study Prospective Study Randomised trial randomised trials receiving regimen SARS-CoV-2 SARS-CoV-2 early treatments. SARS-CoV-2 vaccination SARS-CoV-2 variant serology significant differences significantly higher significantly lower The B.1.1.7 treated vaccination variant [DOI] 10.1007/s10096-022-04464-x PMC 바로가기 [Article Type] Observational Study
Insights from a computational analysis of the SARS-CoV-2 Omicron variant: Host-pathogen interaction, pathogenicity, and possible drug therapeuticsSARS-CoV-2 Omicron 변이체의 컴퓨터 분석에서 얻은 통찰력: 숙주-병원체 상호작용, 병원성 및 가능한 약물 치료법Article Published on 2022-07-012022-09-11 Journal: Immunity, Inflammation and Disease [Category] COVID19(2023년), SARS, 변종, [키워드] ACE2 Affect Alter Analysis analyzed angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 approach binding affinity Characteristics Comparisons computational analysis correlated correlation correlations COVID-19 COVID-19 case COVID-19 cases docking docking result docking results drug Drug efficacy drugs drugs efficacy effective Effectiveness epidemiological evaluate evaluated Factor genomic sequence Host host-pathogen interaction human receptors insight Interaction lack less Lopinavir molecular docking molecular dynamics Molecular dynamics simulation Mutation mutational spectrum Nirmatrelvir NRP1 occurred omicron Omicron variant pathogenic pathogenicity Phylogenetic tree protease Protein Proteins raised Receptor-binding domain reconstructed Research response significant difference significant differences tested the receptor-binding domain the SARS-CoV-2 therapeutic approaches variant [DOI] 10.1002/iid3.639 PMC 바로가기 [Article Type] Article
Follow up of the Humoral Response in Healthcare Workers after the Administration of Two Dose of the Anti SARS-CoV-2 Vaccines-Effectiveness in Delta Variant Breakthrough Infections항 SARS-CoV-2 백신 2회 투여 후 의료 종사자의 체액 반응 추적 - 델타 변이형 돌발 감염에서의 효과Article Published on 2022-06-242022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] anti-S antibody breakthrough infections circulation correlation Coverage Delta delta variant demonstrated doses elicit FIVE HCW HCWs healthcare worker Healthcare workers humoral Humoral response idea IgG IgG antibody implementation infected patient infected patients Infection infections management marker median mRNA vaccine mRNA vaccines new infections no infection other variant other variants pandemic participant Participants Patient PCR positive performed positive positive result predict response SARS-CoV-2 SARS-CoV-2 IgG antibody serological serology Significant significant differences Spain subsequent summer Support the SARS-CoV-2 These data vaccination Vaccine worker [DOI] 10.3390/v14071385 PMC 바로가기 [Article Type] Article
Effect of Cholecalciferol Supplementation on the Clinical Features and Inflammatory Markers in Hospitalized COVID-19 Patients: A Randomized, Open-Label, Single-Center Study입원한 COVID-19 환자의 임상 특징 및 염증 표지자에 대한 콜레칼시페롤 보충제의 효과: 무작위, 공개 라벨, 단일 센터 연구Randomized Controlled Trial Published on 2022-06-232022-09-11 Journal: Nutrients [Category] 바이오마커, 임상, [키워드] 25-hydroxyvitamin D 25(OH)D Affect B cell B cell subsets bolus C-reactive protein caused CD27 CD38 cholecalciferol cholecalciferol supplementation clinical clinical benefit clinical feature Clinical features Concomitant medication Course COVID-19 COVID-19 patients decrease DN B cell DN B cells dose Effect evaluate the effect frequencies Frequency group higher risk Hospitalization Immune status increase in Inflammatory Inflammatory marker inflammatory markers lymphocyte Lymphocyte count lymphocyte counts morbidity neutrophil number of bed observé Patient patients with COVID-19 Randomized receive receiving recent SARS-CoV-2 serum significant difference significant differences significantly higher significantly lower two group two groups Vitamin D Vitamin D supplementation was determined [DOI] 10.3390/nu14132602 PMC 바로가기 [Article Type] Randomized Controlled Trial
Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency공통 가변성 면역 결핍증에서 2개의 ChAdOx1 nCoV-19 후 BNT162b2 부스팅에 의해 유도된 특정 항체 및 T-세포 반응Article Published on 2022-06-172022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 바이오마커, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 immunoglobulin Anti-spike antibody autologous BNT162b2 BNT162b2 vaccine booster vaccination CD19 CD19+ CD3+ CD3+CD4+ CD3+CD8+ CD4+ CD45 CD45+ CD8+ Cell cell count cell counts cell-mediated response ChAdOx1 ChAdOx1 nCoV-19 changes in common common variable immunodeficiency common variable immunodeficiency (CVID) Control Coronavirus-2 COVID-19 infection cumulative cut-off value CVID decrease ELISPOT ELISpot assay evaluated except for flow cytometric healthy control healthy controls healthy individual healthy individuals humoral IFN-γ IFN-γ ELISPOT IFN-γ ELISpot assay IFN-γ producing T cells immune response immunodeficiency Immunoglobulin Immunoglobulin G immunosuppressive immunosuppressive therapy individual interferon interferon-γ Killer cell less Lymphocytes measure morbidity natural killer natural killer cell not different not significant Patient patients positive Primary Immunodeficiency producing protein S raised receiving response Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 shown Side effects significant difference significant differences significantly significantly lower Specific statistically stem cell Stem cell transplantation T cell T cell response T cells tested therapy These data vaccination Vaccinations variable virus-specific T cell virus-specific T-cell with COVID-19 [DOI] 10.3389/fimmu.2022.907125 PMC 바로가기 [Article Type] Article
Prevalence and Dynamics of SARS-CoV-2 Antibodies in the Population of St. Petersburg, Russia러시아 상트페테르부르크 인구에서 SARS-CoV-2 항체의 유병률과 역학Article Published on 2022-06-012022-09-11 Journal: Journal of Epidemiology and Global Health [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody Antibody detection antibody levels Chain Reaction connection coronavirus coronavirus disease COVID-19 database decrease Dynamics effective Epidemiological study Follow-up IgA IgG IgM Immunity Laboratory lockdown measure Measures Patient PCR PCR test polymerase chain polymerase chain reaction Population Post-infection Prevalence proportion Quantitative quarantine remained respiratory Retrospective analysis Russia Saint Petersburg SARS-CoV-2 SARS-CoV-2 detection seropositive seropositive status Seropositivity Seroprevalence severe acute respiratory syndrome Coronavirus significant difference significant differences spread of COVID-19 state test results university was performed [DOI] 10.1007/s44197-022-00041-9 PMC 바로가기 [Article Type] Article
Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19SARS-CoV-2에 대한 아프로티닌 치료: 중등도 COVID-19에 대한 범프로테아제 억제제의 안전성과 효능을 평가하기 위한 무작위 3상 연구Clinical Trial Published on 2022-06-012022-09-11 Journal: European Journal of Clinical Investigation [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] ACE2 addition administration Adverse reaction Adverse reactions anti-inflammatory properties anti-inflammatory property antiviral drug antivirus Aprotinin cleave Clinical outcome clinical trial Composite Contact COVID-19 death discharge double-blind Efficacy evaluate follow-up period furin had no hospital Hospital admission Hospital stay Hospitalization hospitalized patient hospitalized patients host protease host proteases human respiratory viruses ICU admission IMPROVE incidence inhalation therapy inhibiting inhibitor Innate immunity less mechanism Moderate COVID-19 multicentre outcome oxygen Oxygen therapy parameter patients with COVID-19 performed placebo group Pneumonia profiles Protease inhibitor Randomized randomized trial required respiratory viruses resulting Safe Safety SARS-CoV-2 SARS-CoV-2 virus secondary endpoint Secondary endpoints Side effects significant difference significant differences Spanish Spike protein standard treatment the placebo group Treatment with COVID-19 [DOI] 10.1111/eci.13776 PMC 바로가기 [Article Type] Clinical Trial
Adverse events following third dose of mRNA COVID-19 vaccination among nursing home residents who received the primary series1차 시리즈를 받은 요양원 거주자 중 mRNA COVID-19 백신 3차 접종 후 부작용Article Published on 2022-06-012022-09-11 Journal: Journal of the American Geriatrics Society [Category] COVID19(2023년), SARS, 치료기술, [키워드] 95% CI adjust Administered administration Adverse adverse event adverse events adverse events after vaccination booster booster COVID-19 vaccination booster dose CDC COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines dose Electronic health record Electronic health records event event rate event rates false discovery rate genesis Ischemic Stroke medical condition Medical conditions mRNA mRNA vaccine multiple comparisons multiplicity no significant differences nursing home nursing homes occurred prospective cohort reported resident Safety screened significant difference significant differences statistically significant tested vaccination rate venous Venous Thromboembolism [DOI] 10.1111/jgs.17812 PMC 바로가기 [Article Type] Article